Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?

Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients

(2011) C. R. Carter et al.   BLOOD

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

(2011) M. Q. Lacy et al.   BLOOD

How "immunomodulatory" are IMIDs?

(2011) C. S. Mitsiades   BLOOD

Guidelines for the diagnosis and management of multiple myeloma 2011

(2011) Jennifer M. Bird et al.   BRITISH JOURNAL OF HAEMATOLOGY

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY